Absci Corporation (ABSI)
- Previous Close
4.4550 - Open
4.5000 - Bid 4.5200 x 200
- Ask 4.5900 x 500
- Day's Range
4.4700 - 4.6800 - 52 Week Range
1.1110 - 6.7200 - Volume
636,613 - Avg. Volume
1,559,863 - Market Cap (intraday)
517.92M - Beta (5Y Monthly) 2.37
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2000 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.60
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
www.absci.comRecent News: ABSI
Performance Overview: ABSI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABSI
Valuation Measures
Market Cap
517.92M
Enterprise Value
436.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
73.71
Price/Book (mrq)
2.94
Enterprise Value/Revenue
76.29
Enterprise Value/EBITDA
-4.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.75%
Return on Equity (ttm)
-49.08%
Revenue (ttm)
5.72M
Net Income Avi to Common (ttm)
-110.57M
Diluted EPS (ttm)
-1.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
97.66M
Total Debt/Equity (mrq)
9.06%
Levered Free Cash Flow (ttm)
-34.43M